Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Income towards Parent Company (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Income towards Parent Company data on record, last reported at -$21.1 million in Q4 2025.

  • For Q4 2025, Income towards Parent Company rose 78.37% year-over-year to -$21.1 million; the TTM value through Dec 2025 reached -$68.7 million, up 48.69%, while the annual FY2025 figure was -$68.7 million, 47.95% up from the prior year.
  • Income towards Parent Company reached -$21.1 million in Q4 2025 per ACRS's latest filing, down from -$15.3 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at -$4.0 million in Q4 2023 and bottomed at -$97.6 million in Q4 2024.
  • Average Income towards Parent Company over 5 years is -$23.9 million, with a median of -$20.6 million recorded in 2021.
  • Peak YoY movement for Income towards Parent Company: tumbled 66588.89% in 2021, then soared 86.08% in 2023.
  • A 5-year view of Income towards Parent Company shows it stood at -$22.9 million in 2021, then fell by 27.02% to -$29.1 million in 2022, then skyrocketed by 86.08% to -$4.0 million in 2023, then plummeted by 2310.95% to -$97.6 million in 2024, then skyrocketed by 78.37% to -$21.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Income towards Parent Company were -$21.1 million in Q4 2025, -$15.3 million in Q3 2025, and -$16.4 million in Q2 2025.